CAR-T

CARsgen Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative CAR-T cell therapies for the treatment of hematological malignancies and solid tumors. The company has established a comprehensive pipeline including its lead candidate, zevorcabtagene autoleucel (zevor-cel), which has received approval in China for refractory multiple myeloma. CARsgen distinguishes itself through its proprietary technology platforms, such as CycloCAR, which aims to enhance the efficacy of CAR-T cells against solid tumors by co-expressing cytokines and chemokines. With integrated capabilities spanning discovery, clinical development, and GMP manufacturing, the company operates facilities in both China and the United States to support its global clinical trial programs.